JP2012532596A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532596A5
JP2012532596A5 JP2012519013A JP2012519013A JP2012532596A5 JP 2012532596 A5 JP2012532596 A5 JP 2012532596A5 JP 2012519013 A JP2012519013 A JP 2012519013A JP 2012519013 A JP2012519013 A JP 2012519013A JP 2012532596 A5 JP2012532596 A5 JP 2012532596A5
Authority
JP
Japan
Prior art keywords
plasmin
plasminogen
amino acid
variant
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519013A
Other languages
English (en)
Japanese (ja)
Other versions
JP5819293B2 (ja
JP2012532596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/059902 external-priority patent/WO2011004011A1/en
Publication of JP2012532596A publication Critical patent/JP2012532596A/ja
Publication of JP2012532596A5 publication Critical patent/JP2012532596A5/ja
Application granted granted Critical
Publication of JP5819293B2 publication Critical patent/JP5819293B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519013A 2009-07-10 2010-07-09 プラスミノーゲンおよびプラスミンの変異体 Expired - Fee Related JP5819293B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22451409P 2009-07-10 2009-07-10
EP09165237 2009-07-10
US61/224,514 2009-07-10
EP09165237.0 2009-07-10
PCT/EP2010/059902 WO2011004011A1 (en) 2009-07-10 2010-07-09 Variants of plasminogen and plasmin

Publications (3)

Publication Number Publication Date
JP2012532596A JP2012532596A (ja) 2012-12-20
JP2012532596A5 true JP2012532596A5 (enExample) 2013-05-30
JP5819293B2 JP5819293B2 (ja) 2015-11-24

Family

ID=40972886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519013A Expired - Fee Related JP5819293B2 (ja) 2009-07-10 2010-07-09 プラスミノーゲンおよびプラスミンの変異体

Country Status (13)

Country Link
US (1) US9226953B2 (enExample)
EP (1) EP2451835A1 (enExample)
JP (1) JP5819293B2 (enExample)
KR (1) KR20120050442A (enExample)
CN (1) CN102482338B (enExample)
AU (1) AU2010270146B9 (enExample)
CA (1) CA2767612A1 (enExample)
IL (1) IL217113A0 (enExample)
MX (1) MX2012000475A (enExample)
NZ (1) NZ597452A (enExample)
RU (1) RU2564131C2 (enExample)
WO (1) WO2011004011A1 (enExample)
ZA (1) ZA201200191B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
ES2583082T3 (es) 2011-01-05 2016-09-19 Thrombogenics N.V. Variantes de plasminógeno y plasmina
WO2013024074A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
ES2628321T3 (es) * 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
WO2014160281A2 (en) * 2013-03-14 2014-10-02 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
EP2821081A1 (en) 2013-07-05 2015-01-07 ResuSciTec GmbH Protective solution for preventing or reducing reperfusion injury of the brain and the whole body
DE102014107567B3 (de) * 2014-05-28 2015-11-05 Papierfabrik August Koehler Se Wärmeempfindliches Aufzeichnungsmaterial
EP3233111B1 (en) * 2014-12-19 2024-08-07 Kedrion Biopharma Inc. Pharmaceutical composition comprising plasminogen and uses thereof
RU2597782C1 (ru) * 2015-08-25 2016-09-20 Василий Николаевич Яковлев Способ определения содержания продуктов протеолиза в плазме крови и диагностическая тест-система для его осуществления
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TWI653982B (zh) * 2015-12-18 2019-03-21 大陸商深圳瑞健生命科學研究院有限公司 Method for preventing or treating acute and chronic thrombosis
CN106890320A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
EP3391901B1 (en) * 2015-12-18 2023-07-05 Talengen International Limited Plasminogen for use in treating liver tissue damage
DK3391902T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
CA3008495A1 (en) 2015-12-18 2017-06-22 Talengen International Limited Method for preventing and treating cervical erosion
WO2017101873A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
CN110114080A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗皮肤纤维化的方法
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
JP7171572B2 (ja) 2016-12-15 2022-11-15 タレンゲン インターナショナル リミテッド 糖尿病を治療するための新しい方法
CN108210917A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
WO2018108161A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
JP7182793B2 (ja) * 2016-12-15 2022-12-05 タレンゲン インターナショナル リミテッド 病理学的腎組織損傷を予防及び治療するための方法
CN110366425A (zh) * 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
CN108210910A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗系统性硬化症的药物及其用途
TWI714862B (zh) 2017-06-19 2021-01-01 大陸商深圳瑞健生命科學硏究院有限公司 一種調控glp-1/glp-1r的方法和藥物
CN113795274A (zh) * 2019-05-10 2021-12-14 泰伦基国际有限公司 一种治疗肌萎缩侧索硬化的方法和药物
CA3176937A1 (en) * 2020-03-24 2021-09-30 Talengen International Limited Method and drug for promoting degradation of misfolded protein and aggregate thereof
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
CN113755476B (zh) * 2021-10-14 2023-04-11 北京农学院 蛆激酶制备方法及其用途
CN119331857B (zh) * 2024-12-19 2025-05-16 南通大学 一种新型重组蛋白Plasminogen-CTM及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3208908A (en) 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US4122158A (en) 1976-09-23 1978-10-24 Alza Corporation Topical therapeutic preparations
NZ191320A (en) 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
IT1194135B (it) 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
FI915149A0 (fi) 1989-05-01 1991-10-31 Univ Notre Dame Du Lac Foerfarande och material foer expression av humant plasminogen i ett eukaryotiskt cellsystem som saknar en laegesspecifik plasminogenaktivator.
US5087572A (en) 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
AT402367B (de) 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US5288489A (en) 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
US5879923A (en) 1995-06-26 1999-03-09 Daiichi Pure Chemicals Co., Ltd. Stable plasmin solution
JP4426650B2 (ja) * 1996-05-03 2010-03-03 アボット・ラボラトリーズ 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
JP4577992B2 (ja) * 1998-09-29 2010-11-10 リューベン・リサーチ・アンド・デベロップメント・ベー・ゼット・ウェー 虚血性卒中の処置用の組成物を調製するための、α２抗プラスミンをインビボで減少する化合物の使用
US20040081643A1 (en) 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US6585972B2 (en) 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
DK1194528T3 (da) 1999-07-14 2007-07-09 D Collen Res Foundation Vzw Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
JP2004508006A (ja) * 2000-02-08 2004-03-18 ノースウエスタン　ユニバーシティ アンギオスタチンを生成するための方法および組成物
AU2002218890A1 (en) * 2000-12-21 2002-07-01 Thromb-X N.V. A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
US20020139378A1 (en) 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
EP1472346A2 (de) * 2002-02-06 2004-11-03 N-Zyme BioTec GmbH Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
WO2004045558A2 (en) 2002-11-18 2004-06-03 President And Fellows Of Harvard College Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
EP1706079B1 (en) 2003-08-14 2013-02-20 ThromboGenics N.V. Antibodies against factor viii with modified glycosylation in the variable region
EP1713921A2 (en) * 2004-02-11 2006-10-25 Biolex, Inc. Expression of plasminogen and microplasminogen in duckweed
CN1253560C (zh) 2004-03-01 2006-04-26 宁夏大学 组织型纤溶酶原激活剂缺失/点突变体基因转染细胞株
JP5026254B2 (ja) 2004-04-22 2012-09-12 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007047874A2 (en) 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20070134231A1 (en) 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070134230A1 (en) 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
EP2056864B1 (en) 2006-08-28 2013-12-11 Omnio Healer AB Candidates against infection
GB2455262A (en) 2006-09-29 2009-06-10 Proteomtech Inc Methods for production of recombinant plasminogen and plasmin polypeptides
WO2009073471A1 (en) 2007-11-29 2009-06-11 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
WO2009073457A1 (en) 2007-11-30 2009-06-11 Bausch & Lomb Incorporated Methods and compositions for the rescue of a filtering bleb
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
ES2583082T3 (es) 2011-01-05 2016-09-19 Thrombogenics N.V. Variantes de plasminógeno y plasmina
WO2013024074A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants

Similar Documents

Publication Publication Date Title
JP2012532596A5 (enExample)
RU2012103949A (ru) Варианты плазминогена и плазмина
RU2604807C2 (ru) Варианты плазминогена и плазмина
JP6000353B2 (ja) プラスミノーゲンおよびプラスミンの変異体
US20210330762A1 (en) Medical application of mutant plasminogen and plasmin polypeptide therapeutics
CA2904444A1 (en) Dual reactivity potent kunitz inhibitor of fibrinolysis
HK1191054A (en) Plasminogen and plasmin variants
HK1191054B (en) Plasminogen and plasmin variants
HK1193747A (en) Plasminogen and plasmin variants
NZ612836B2 (en) Plasminogen and plasmin variants
CN1560240A (zh) 组织型纤溶酶原激活剂缺失突变体基因转染细胞株
WO2000063394A9 (en) A polypeptide having amidolytic activity for a serpin
HK1167265B (en) Variants of plasminogen and plasmin